---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-035993"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2026-08-04T20:05:47+00:00"
generated_at: "2026-08-04T20:07:27.535969+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals gets Nasdaq bid-price extension to Feb 1, 2027; notes Nuclea Energy deal

## Summary
- Nasdaq granted 180-day extension until Feb 1, 2027 to meet $1 minimum bid price for 10 consecutive days.
- Company meets all other Nasdaq listing requirements except the bid price rule.
- Company may effect a reverse stock split if needed to cure the deficiency.
- Company continues to advance business combination with Nuclea Energy Inc. (Morpheus microreactor).

## SEC filing metadata
- accession: 0001493152-26-035993
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2026-08-04T20:05:47+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/0001493152-26-035993-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315226035993/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-035993
- JSON: https://secwatch.observer/filing/0001493152-26-035993.json
- Plain text: https://secwatch.observer/filing/0001493152-26-035993.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.